Cargando…
No change in small low‐density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial
Autor principal: | Hirano, Tsutomu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034948/ https://www.ncbi.nlm.nih.gov/pubmed/36708089 http://dx.doi.org/10.1111/jdi.13983 |
Ejemplares similares
-
The influence of triglycerides on small dense low‐density lipoprotein cholesterol levels is attenuated in low low‐density lipoprotein‐cholesterol range: Implications for the negative results of the PROMINENT trial
por: Hirano, Tsutomu, et al.
Publicado: (2023) -
Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia
por: Hida, Yuki, et al.
Publicado: (2023) -
Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy
por: Hirano, Tsutomu, et al.
Publicado: (2023) -
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017) -
Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)